Nomination withdrawn — not under FDA review
Where to Buy CJC-1295
This board is empty, and unlike the other empty boards on this site there is no open question sitting behind it.
CJC-1295 is sold widely and is not hard to find, and it gets no seller list here. The dated status note on this board sets out where the compound actually stands, and it does not describe a decision in progress.
That distinction matters enough to state up front. Some empty boards on this site mark a question that is genuinely open. This one does not, and writing it in the same language would leave a reader with the impression that CJC-1295 is somewhere in a queue.
So no route to a future table is sketched here, because sketching one would be an invention. What is recorded instead is the position as it stands, with the date it was checked attached to it.
Regulatory status, as of September 2026
CJC-1295 was not reviewed at the FDA Pharmacy Compounding Advisory Committee meeting held July 23-24, 2026. Its nomination to the Section 503A bulk drug substances list was withdrawn. So there is no vote, no recommendation and no decision pending on it. That is a different situation from the peptides the committee did consider, and it is not written here as though it were the same one. Nothing about CJC-1295 is scheduled, under review, or moving. There is no basis for saying what happens next, so nothing is said. This page exists to state that plainly, rather than leave the compound looking like it is somewhere in a queue.
Nothing is pending, so there is nothing to wait on and no path to describe honestly. If the regulatory position changes on the public record, the change gets dated here, along with a fresh look at whether a board belongs on the page at all.
What this board covers
Nothing is ranked here, and no forecast replaces the ranking. A compound earns a scored board on this site once a licensed US telehealth seller dispenses it under facts a reader can verify independently. CJC-1295 is not in that position, and the status note explains the situation rather than promising a change to it.
What CJC-1295 is
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone. It is designed to act on the same pathway the body uses to signal growth hormone release. It is not an FDA-approved drug in the United States. What follows covers where it stands with regulators and tells nobody to use it.
What the evidence shows
The growth-hormone-axis mechanism behind CJC-1295 is real and measurable, which is why the evidence grade is limited rather than absent. What is missing is the long-term human outcome data that the claims made for it in the consumer market would require. Short-term hormone measurements are not outcomes. Most of what is written about this compound treats the two as interchangeable. No trial count appears here.
What to watch for
- One name covering two different molecules. The long-acting version and the version sold without the modification behave differently, and vials frequently do not make clear which is inside.
- Human data on the long-acting form used to sell the other one. The evidence and the product in the cart are often not the same thing, and no listing points that out.
- CJC-1295 sold as a blend with another peptide in a single vial. A blend hides how much of each compound is present and makes any comparison between sellers guesswork.
- A research-labeled vial presented as a prescription product. The label records how the material was sold, and a clinical-looking storefront does not change it.
Frequently asked questions
Why is this board empty when other compounds here are described as pending?
Because empty covers two different situations on this site. Some boards mark a question that is open. This one marks a compound with no such question attached, and the dated status note keeps the two apart.
Is a decision about CJC-1295 coming?
Nothing on the public record supports saying so, and nothing is guessed at here. The dated status note states the position plainly, including what is absent from it.
Sellers list CJC-1295 today. Why are they not compared?
Their material is not dispensed under terms a reader can verify from outside the storefront. A comparison table needs checkable facts, and a listing with none is not one.
Does an empty board mean CJC-1295 is dangerous?
No. The board reflects what can be lawfully dispensed and independently checked. It is not a safety verdict, and this site does not issue one it cannot support.
Is CJC-1295 the same as ipamorelin?
No. They act through different receptors and are often sold together in one vial, which is why they are confused. The comparison article on the two lays out what actually separates them.